Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live

United States & Boehringer Ingelheim

8 shared events · Importance 3 · Last updated Sep 22, 2026

Importance
3
Shared Events
8
Actions
0
Sentiment
0
Live sentiment trends, interaction importance charts, and action volume tracking available on the Ergen Dashboard
69
Business
United States: The US is part of North America, which held the largest market share in 2025, supported by strong regulatory frameworks and advanced manufacturing.
Boehringer Ingelheim: Boehringer Ingelheim is a key player in the antibody therapeutics market, benefiting from the projected market growth.
Jul 28, 2026 · 6 articles
49
Regulatory
United States: Cited as a key competitor attracting far more pharmaceutical investment, with healthcare spending at about 2% of GDP versus Europe's 1%. Its more aggressive policies are said to be drawing capital and launches away from Europe.
Boehringer Ingelheim: One of the nine signatories of the open letter urging EU action on medicine spending, trials and IP protection. Its participation signals shared industry concern over European competitiveness.
Sep 22, 2026 · 6 articles
32
Tech
United States: The study focuses on U.S. populations, particularly the Southern Appalachian region, and may influence national screening guidelines and public health policy.
Boehringer Ingelheim: Boehringer Ingelheim's past deal with Hanmi Pharm for olmutinib is mentioned as a historical example of EGFR therapy development challenges.
Sep 17, 2026 · 6 articles
22
Tech
United States: The study population is U.S.-based, and findings may influence public health recommendations.
Boehringer Ingelheim: Andrew T. Chan served as a consultant; no direct impact.
Aug 17, 2026 · 20 articles
22
Tech
United States: Obesity epidemic in children drives demand for treatments; policy implications.
Boehringer Ingelheim: Orandi served on advisory board; not directly involved.
Sep 04, 2026 · 7 articles
14
Business
United States: Mentioned in the context of U.S. government responses to Chinese innovation, but not directly involved in the transaction.
Boehringer Ingelheim: Mentioned as a previous partner of Grand Pharmaceutical Group, highlighting the platform's track record but not directly affected by this deal.
Jul 20, 2026 · 11 articles
0
International
Boehringer Ingelheim: Boehringer Ingelheim managers are traveling with Friedrich Merz, indicating a focus on deepening cooperation in the pharmaceuticals sector with India.
Jan 11, 2026 · 6 articles
0
Regulatory
Dec 19, 2025 · 7 articles
ERGEN INTELLIGENCE
Explore this relationship live

Track how United States and Boehringer Ingelheim interact across events, view sentiment trends, and discover connected entities.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.